Ameriprise Financial Inc. Has $121.75 Million Holdings in Cencora, Inc. (NYSE:COR)

Ameriprise Financial Inc. raised its position in shares of Cencora, Inc. (NYSE:COR) by 96.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 541,881 shares of the company’s stock after acquiring an additional 266,011 shares during the period. Ameriprise Financial Inc. owned approximately 0.28% of Cencora worth $121,747,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Alteri Wealth LLC acquired a new position in Cencora in the 4th quarter valued at $275,000. Ancora Advisors LLC grew its stake in shares of Cencora by 5.2% in the fourth quarter. Ancora Advisors LLC now owns 3,877 shares of the company’s stock valued at $871,000 after acquiring an additional 191 shares in the last quarter. Aptus Capital Advisors LLC increased its position in Cencora by 117.3% during the fourth quarter. Aptus Capital Advisors LLC now owns 2,647 shares of the company’s stock worth $595,000 after acquiring an additional 1,429 shares during the period. AXA S.A. raised its stake in Cencora by 0.9% in the 4th quarter. AXA S.A. now owns 267,889 shares of the company’s stock worth $60,189,000 after purchasing an additional 2,413 shares in the last quarter. Finally, Wahed Invest LLC boosted its holdings in Cencora by 6.0% in the 4th quarter. Wahed Invest LLC now owns 4,275 shares of the company’s stock valued at $961,000 after purchasing an additional 243 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Up 4.5 %

Shares of Cencora stock opened at $304.04 on Thursday. The firm has a market capitalization of $58.96 billion, a PE ratio of 43.25, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm’s 50 day moving average is $275.33 and its 200 day moving average is $252.65. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. During the same quarter in the prior year, the firm earned $3.80 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

COR has been the topic of several recent research reports. Bank of America raised their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $290.00.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock worth $13,580,967 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.